Drug induced encephalopathy in six epileptic patients: Topiramate? Valproate? Or both?

Human Psychopharmacology

Volumn 19, Issue 3, 2004, Pages 193-203

  Latour, Patrick ^a   Biraben, Arnaud ^b   Polard, Elisabeth ^b   Bentué Ferrer, Danièle ^c   Beauplet, Anne ^b   Tribut, Olivier ^b   Allain, Hervé ^c  

^a SERVICE DE RHUMATOLOGIE   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Anticonvulsants; Drug interactions; Encephalopathy; Epilepsy; Pharmacovigilance; Topiramate; Valproate

Indexed keywords

AMMONIA; BROMAZEPAM; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; FLUOXETINE; LAMOTRIGINE; LEVOTHYROXINE SODIUM; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; AMMONIA BLOOD LEVEL; ANOREXIA; ANTEROGRADE AMNESIA; APHASIA; APRAXIA; ARTICLE; ASTHENIA; BRAIN DISEASE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DISORIENTATION; DROWSINESS; DRUG CROSS REACTIVITY; DRUG MECHANISM; DRUG WITHDRAWAL; EEG ABNORMALITY; EPILEPSY; FEMALE; FLAPPING TREMOR; HEAT STRESS; HIGH RISK PATIENT; HUMAN; HYPERAMMONEMIA; LANGUAGE DISABILITY; MALE; MENTAL DISEASE; MONOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; STUPOR; TREMOR;

ADOLESCENT; ADULT; AMMONIA; ANTICONVULSANTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; MALE; NEUROTOXICITY SYNDROMES; VALPROIC ACID;

EID: 1942520331     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.575     Document Type: Article

References (34)

1. Biraben A, Genton P. 2000a. Utilisation pratique du topiramate (1ère partie). Analyse rétrospective multicentrique de l'efficacité du topiramate en association selon la forme topographique de l'épilepsie partielle. Rev Neurol 156: 993-999.
2. Biraben A, Genton P. 2000b. Utilisation pratique du topiramate (2ème partie). Analyse rétrospective multicentrique de sa sécurité d'emploi. Rev Neurol 156: 1120-1125.
3. Bourrier P, Varache N, Alquier P, et al. 1988. Oedème cerebral avec hyperammoniémie au cours d'une intoxication par le valpromide. Presse Med 17: 2063-2066.
4. Coulter DL. 1991. Carnitine, valproate and toxicity. J Child Neurol 6: 7-14.
5. Dogson SJ, Shank RP, Maryanoff BE. 2000. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41(Suppl. 1): S35-S39.
6. Duarte J, Macias S, Coria F, et al. 1993. Valproate-induced coma: case report and literature review. Ann Pharmacother 27: 582-583.
7. Farrell K, Abbott FS, Orr JM, et al. 1986. Free and total serum valproate concentrations: their relationship to seizure control, liver enzymes and plasma ammonia in children. Can J Neurol Sci 13: 252-255.
8. Faught E. 1999. Clinical studies of topiramate. Drugs Today 35: 49-57.
9. Fraser CM, Sills GJ, Forrest G, et al. 1999. Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. Br J Pharmacol 126: 1634-1638.
10. Garnett WR. 2000. Clinical pharmacology of topiramate: a review. Epilepsia 41(Suppl. 1): S61-S65.
11. Gerber PE, Hamiwka L, Connelly MB, et al. 2000. Factors associated with behavioural and cognitive abnormalities in children receiving topiramate. Pediatric Neurol 22: 200-203.
12. Guberman A, Neto W, Gassmann-Mayer C. 2000. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 106: 183-189.
13. Hamer HM, Knake S, Schomburg U, et al. 2000. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 54: 230-232.
14. Häussinger D, Kaiser S, Stehle T, et al. 1986. Liver carbonic anhydrase and urea synthesis. The effect of diuretics. Biochem Pharmacol 35: 3317-3322.
15. Honeycutt D, Callahan K, Rutledge L, et al. 1992. Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Neurology 42: 666-668.
16. Kerleau JM, Bohu PA, Héron F, et al. 1994. Encéphalopathie induite par le valproate de sodium. Rev Med Int 15: 363-364.
17. Kossak BD, Schmidt-Sommerfeld E, Schoeller DA, et al. 1993. Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine. Neurology 43: 2362-2368.
18. Kwan P, Brodie MJ. 2001. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 357: 216-222.
19. Longin E, Teich M, Koelfen W, et al. 2002. Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia 43: 451-454.
20. Marescaux C, Warter JM, Micheletti G, et al. 1982. Stuporous episodes during treatment with sodium valproate: report of seven cases. Epilepsia 23: 297-305.
21. Marini AM, Zaret BS, Beckner RR. 1988. Hepatic and renal contributions to valproic acid-induced hyperammonemia. Neurology 38: 365-371.
22. Moore N, Biour M, Paux G, et al. 1985. Adverse drug reaction monitoring: doing it the French way. Lancet 2: 1056-1058.
23. Murakami K, Sugimoto T, Woo M, et al. 1996. Effect of L-carnitine supplementation on acute valproate intoxication. Epilepsia 37: 687-689.
24. Murphy JV, Marquardt K. 1982. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol 39: 591-592.
25. Oechsner M, Steen C, Stürenburg HJ, et al. 1998. Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency. J Neurol Neurosurg Psychiatry 64: 680-682.
26. Peeters K, Adriaenssen I, Wapenaar R, et al. 2003. A pooled analysis of adjunctive topiramate in refractory epilepsy. Acta Neurol Scand 108: 9-15.
27. Privitera MD. 1997. Topiramate: a new anti-epileptic drug. Ann Pharmacother 31: 1164-1173.
28. Solomon GE. 2000. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 55: 606.
29. Verbiest HBC, Straver JS, Colombo JP, et al. 1992. Carbamyl phosphatase synthetase-1 deficiency discovered after valproic acid-induced coma. Acta Neurol Scand 86: 275-279.
30. Vossler GD, Wilensky J, Cawthon DF, et al. 2002. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. Epilepsia 43: 154-159.
31. Wang V, Saab S. 2003. Ammonia levels and the severity of hepatic encephalopathy. Am J Med 114: 237-238.
32. Zaccara G, Campostrini R, Paganini M, et al. 1984. Acute changes of blood ammonia may predict short-term adverse effects of valproic acid. Neurology 34: 1519-1521.
33. Zaccara G, Campostrini R, Paganini M, et al. 1987. Long-term treatment with sodium valproate: monitoring of venous ammonia concentrations and adverse effects. Ther Drug Monit 9: 34-40.
34. Zaret BS, Beckner R, Marini AM, et al. 1982. Sodium valproate induced hyperammonemia without clinical dysfunction. Neurology 32: 206-208.